Abstract
A group of 11 heavily pretreated patients receiving low-dose thalidomide was compared with a similar group of 10 patients with refractory myeloma treated with a convention-al oral chemotherapy. This study shows that thalidomide is not only effective in controlling the neoplastic clone but more-over, thanks to its low toxicity, allows out-patient management of these subjects.
Vol. 87 No. 3 (2002): March, 2002 : Letters to the Editor
Published By
Ferrata Storti Foundation, Pavia, Italy
